Hainan Haiyao (000566) disclosed its 2024 performance forecast on the evening of January 27, and it is expected to achieve operating income of 1 billion to 1.2 billion yuan in 2024; net profit attributable to the parent company will be a loss of 900 million to 1.3 billion yuan, compared with a loss of 106 million yuan in the same period last year; net profit excluding non-recurring items will be a loss of 700 million to 1 billion yuan, compared with a loss of 410 million yuan in the same period last year; basic earnings per share will be -0.6937 yuan/share to -1.002 yuan/share. Based on the closing price on January 27, Hainan Haiyao's current price-to-earnings ratio (TTM) is about -4.29 times to -6.2 times, price-to-book ratio (LF) is about 3.16 times, and price-to-sales ratio (TTM) is about 5.07 times.

According to the data, the company's main business is the research, development, production and sales of antibiotic series, gastrointestinal medicine series, anti-tumor drug series, raw materials and intermediates series and other products supporting preparations.

According to the announcement, the reason for the change in the company's performance is that the estimated amount of asset impairment losses and credit impairment losses in this reporting period is about -700 million yuan, mainly due to the impairment test of assets such as long-term equity investments, goodwill and other receivables in this reporting period. According to the requirements of the "Enterprise Accounting Standards", the impairment provision is made for assets with recoverable amounts lower than the book value.

The estimated amount of gains and losses from changes in fair value is about -400 million yuan, mainly due to the recognition of losses from changes in fair value of trading financial assets in this reporting period.

Source: https://finance.eastmoney.com/